This company is no longer active
YMTX Stock Overview
Yumanity Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of treatments for neurodegenerative diseases caused by protein misfolding. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Yumanity Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$13.23 |
| 52 Week High | US$26.45 |
| 52 Week Low | US$6.65 |
| Beta | 0 |
| 1 Month Change | 2.16% |
| 3 Month Change | 15.24% |
| 1 Year Change | -41.30% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -91.45% |
Recent News & Updates
Recent updates
Shareholder Returns
| YMTX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -8.3% | 3.6% | 1.8% |
| 1Y | -41.3% | -3.7% | 24.9% |
Return vs Industry: YMTX underperformed the US Biotechs industry which returned -4.2% over the past year.
Return vs Market: YMTX underperformed the US Market which returned 14.1% over the past year.
Price Volatility
| YMTX volatility | |
|---|---|
| YMTX Average Weekly Movement | 9.0% |
| Biotechs Industry Average Movement | 11.3% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 18.9% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: YMTX has not had significant price volatility in the past 3 months.
Volatility Over Time: YMTX's weekly volatility has decreased from 16% to 9% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 41 | Richard Peters | www.yumanity.com |
Yumanity Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of treatments for neurodegenerative diseases caused by protein misfolding. The company focuses on discovering disease-modifying therapies to treat neurodegenerative diseases, including Parkinson’s disease, dementia with Lewy bodies, multiple system atrophy, amyotrophic lateral sclerosis, and frontotemporal lobar degeneration. Its lead program is YTX-7739, a novel small molecule that is in Phase I clinical trial for the treatment of Parkinson’s disease and related disorders of a-synuclein.
Yumanity Therapeutics, Inc. Fundamentals Summary
| YMTX fundamental statistics | |
|---|---|
| Market cap | US$143.63m |
| Earnings (TTM) | -US$32.00m |
| Revenue (TTM) | US$4.84m |
29.7x
P/S Ratio-4.5x
P/E RatioIs YMTX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| YMTX income statement (TTM) | |
|---|---|
| Revenue | US$4.84m |
| Cost of Revenue | US$12.45m |
| Gross Profit | -US$7.60m |
| Other Expenses | US$24.40m |
| Earnings | -US$32.00m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.95 |
| Gross Margin | -156.97% |
| Net Profit Margin | -660.75% |
| Debt/Equity Ratio | 0% |
How did YMTX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2022/12/19 13:59 |
| End of Day Share Price | 2022/12/16 00:00 |
| Earnings | 2022/09/30 |
| Annual Earnings | 2021/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Yumanity Therapeutics, Inc. is covered by 4 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Andrew Fein | H.C. Wainwright & Co. |
| Michael Yee | Jefferies LLC |
| Kelechi Chikere | Jefferies LLC |